AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics Reports First Quarter 2022 Financial Results

06 May 2022 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

02 May 2022 06:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

25 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

08 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

26 Nov 2021 16:28:49 By Nasdaq GlobeNewswire

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment

12 Nov 2021 07:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

09 Nov 2021 15:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

19 Oct 2021 15:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

05 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference

07 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

13 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

14 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment

08 Jul 2021 10:10:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

25 Jun 2021 10:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH

21 Jun 2021 07:00:02 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress

01 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

28 May 2021 15:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

13 May 2021 06:00:01 By Nasdaq GlobeNewswire